Study stresses comprehensive cholesterol care
Published: 05:12 PM,Dec 10,2024 | EDITED : 09:12 PM,Dec 10,2024
The findings emphasise the need for comprehensive strategies to address treatment gaps.
MUSCAT: The Medical Research Centre at Sultan Qaboos University, in collaboration with Abbott, announced the completion of the Gulf study on the role of triglycerides in managing cardiovascular disease indicators.
This study was conducted in five Gulf countries namely Oman, the United Arab Emirates, Kuwait, Bahrain and Qatar. The study aimed to collect and analyse clinical data on the correlation between elevated triglyceride levels in high-risk patients and the control of cardiovascular disease indicators, as well as the most commonly used methods for treatment and follow-up.
The study concluded that a significant percentage (55 per cent) of very high-risk patients in the Gulf region, despite adhering to statin medications at prescribed doses and achieving target levels of low-density lipoprotein cholesterol (LDL-C), did not reach the target levels of non-high-density lipoprotein cholesterol (non-HDL-C).
Non-HDL-C includes all atherogenic lipoproteins, such as triglyceride-rich lipoprotein particles.
The findings emphasise the need for comprehensive strategies to address treatment gaps, focusing on reducing LDL-C and non-HDL-C cholesterol levels through enhanced lifestyle interventions and precise treatments targeting triglyceride-rich lipoprotein particles. These strategies can significantly reduce the burden of cardiovascular diseases.
This study was conducted in five Gulf countries namely Oman, the United Arab Emirates, Kuwait, Bahrain and Qatar. The study aimed to collect and analyse clinical data on the correlation between elevated triglyceride levels in high-risk patients and the control of cardiovascular disease indicators, as well as the most commonly used methods for treatment and follow-up.
The study concluded that a significant percentage (55 per cent) of very high-risk patients in the Gulf region, despite adhering to statin medications at prescribed doses and achieving target levels of low-density lipoprotein cholesterol (LDL-C), did not reach the target levels of non-high-density lipoprotein cholesterol (non-HDL-C).
Non-HDL-C includes all atherogenic lipoproteins, such as triglyceride-rich lipoprotein particles.
The findings emphasise the need for comprehensive strategies to address treatment gaps, focusing on reducing LDL-C and non-HDL-C cholesterol levels through enhanced lifestyle interventions and precise treatments targeting triglyceride-rich lipoprotein particles. These strategies can significantly reduce the burden of cardiovascular diseases.